Lilly’s breast cancer drug Verzenio approved in EU

Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.

Verzenio (abemaciclib) is a CDK4 and 6 inhibitor, and has been approved by the European Commission in women living with HR+, HER2- advanced breast cancer, in combination with an aromatase inhibitor or fulvestrant.